Medicxi's new €500M fund Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 14 November, 2025

Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

presented by Da­ta Built for Dis­cov­ery: Ad­vanc­ing Pre­ci­sion Med­i­cine Through In­ten­tion­al De­sign

news Merck to buy Cidara and its preventive influenza biologic for $9.2B Lundbeck fires the first shot in a bidding war with Alkermes over sleep biotech Vicebio and Versanis backer Medicxi closes new €500M biotech fund Peer Review Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine Dec 16 11:30am ET Maintaining EU GMP Annex I expectations while adopting new standards for prefilled syringe systems sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

Clinical trials are slower and costlier than ever — yet the pressure to move fast has never been higher. Join Endpoints News for a conversation on what’s shifting, what’s working, and where the industry goes next. Sign up today.

endpoints pharma UK gives drugmakers third extension to opt out of medicine rebate scheme Law to end government shutdown also seeks to accelerate prescription-to-OTC drug switches FDA approves Kura and Kyowa Kirin's drug for form of acute myeloid leukemia Pfizer closes up to $10B deal for obesity biotech Metsera AbbVie, Alphabet’s Calico end 11-year partnership in aging research

in case you missed it 1. Q&A: BioNTech co-founders discuss bispecific efforts, Bristol Myers deal, and the irony of competing with Pfizer 2. Merck KGaA still in tariff talks with the White House, weeks after deal was announced  3. Gate Bioscience captures another $65M with new take on protein degradation 4. Q&A: Brent Saunders on pushing Bausch out of neutral, scrutinizing new hires and why TrumpRx matters